Pelthos Therapeutics Inc. (PTHS) News
Track canonical SquawkNews coverage tagged to PTHS, Pelthos Therapeutics Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Pelthos Therapeutics reports Q2 2026 revenue growth on Zelsuvmi demand
Pelthos Therapeutics said second-quarter 2026 net product revenue rose to $15.4 million from $10.7 million in Q1, as Zelsuvmi prescription units increased 48% to 11,925.
EARNINGS | Aug 13, 2026, 01:20 PM UTC
L
Pelthos Therapeutics reports second-quarter 2026 financial results
Pelthos Therapeutics (PTHS) announces its second-quarter 2026 financial results, with no EPS, revenue, or guidance figures provided in the feed.
EARNINGS | Aug 13, 2026, 11:10 AM UTC
L
PTHS - Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
PTHS - Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
EARNINGS | Aug 03, 2026, 12:01 PM UTC
L
Pelthos Therapeutics Joins The Russell 3000E Growth Benchmark, Russell Microcap And Russell Microcap Growth Benchmark Indexes
Pelthos Therapeutics Inc. (NYSE: PTHS ), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, ("Pelthos"), today announced that the company was added as a memb
EQUITY | Jun 30, 2026, 08:17 PM UTC